New agents for orthopaedic thromboprophylaxis: Caution essential, but time will tell

ANZ Journal of Surgery

Volumn 79, Issue 11, 2009, Pages 773-774

  Verma, Abhishek K ^a  

^a GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; BLOOD CLOTTING FACTOR 10; DABIGATRAN; ENOXAPARIN; FRESH FROZEN PLASMA; HEPARIN; PROTAMINE SULFATE; RIVAROXABAN; THROMBIN; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; LIVER FUNCTION; ORTHOPEDIC SURGERY; POSTOPERATIVE THROMBOSIS; SHORT SURVEY; SIDE EFFECT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ANTICOAGULANTS; BENZIMIDAZOLES; ENOXAPARIN; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; PYRIDINES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 70449474467     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2009.05099.x     Document Type: Short Survey

References (9)

1. Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med. J. Aust. 2009 190 : 379 383.
2. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008 358 : 2765 2775.
3. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study. Lancet 2008 372 : 31 9.
4. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008 358 : 2776 2786.
5. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J. Am. Coll. Cardiol. 2005 46 : 1986 1995.
6. Eriksson B, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007 370 : 949 956. (Pubitemid 47393577)
7. Eriksson B, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomised trial. J. Thromb. Haemost. 2007 5 : 2178 2185. (Pubitemid 47617868)
8. Rosencher N, Bellamy L, Arnaout L. Should new oral anticoagulants replace low molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Arch. Cardiovasc. Dis. 2009 102 (4 327 333.
9. Wolowacz SE, Roskell NS, Maciver F et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin. Ther. 2009 31 : 194 212.